Tran Ellen T, Patel Ruchi A, Chariyamane Amogh, Ray Ratna B
Department of Pathology, Saint Louis University, MO, USA.
FEBS Open Bio. 2025 Apr 15. doi: 10.1002/2211-5463.70042.
Head and neck squamous cell carcinoma (HNSCC) is a major global health burden, often associated with poor prognosis and limited therapeutic options. Long non-coding RNAs (lncRNAs), a diverse group of non-coding RNA molecules > 200 nucleotides in length, have emerged as critical regulators in the pathogenesis of HNSCC. This review summarizes the mechanisms through which certain lncRNAs regulate chromatin modification, mRNA splicing, and interactions with RNA-binding proteins and contribute to the development and progression of HNSCC. Interaction of lncRNAs with key oncogenic pathways, such as PI3K/AKT and Wnt/β-catenin, highlights their importance in tumor progression. The role of lncRNAs, such as ELDR, MALAT1, NEAT1, HOTAIR, and UCA1, which promote cell proliferation, metastasis, immune evasion, and therapy resistance is discussed. Moreover, several lncRNAs are being evaluated in clinical trials for their potential as biomarkers, reflecting their clinical significance. We further address the challenges and opportunities for targeting lncRNA therapeutically, highlighting the promise of lncRNA-based interventions for personalized cancer treatment. Gaining insight into the function of lncRNAs in HNSCC could pave the way for novel therapeutic strategies to potentially improve patient outcomes.
头颈部鳞状细胞癌(HNSCC)是一项重大的全球健康负担,常与预后不良和治疗选择有限相关。长链非编码RNA(lncRNA)是一类长度超过200个核苷酸的多样的非编码RNA分子,已成为HNSCC发病机制中的关键调节因子。本综述总结了某些lncRNA调节染色质修饰、mRNA剪接以及与RNA结合蛋白相互作用并促进HNSCC发生发展的机制。lncRNA与关键致癌途径(如PI3K/AKT和Wnt/β-连环蛋白)的相互作用突出了它们在肿瘤进展中的重要性。讨论了ELDR、MALAT1、NEAT1、HOTAIR和UCA1等lncRNA促进细胞增殖、转移、免疫逃逸和治疗抗性的作用。此外,几种lncRNA正在临床试验中评估其作为生物标志物的潜力,这反映了它们的临床意义。我们进一步探讨了针对lncRNA进行治疗的挑战和机遇,强调了基于lncRNA的干预措施在个性化癌症治疗中的前景。深入了解lncRNA在HNSCC中的功能可为潜在改善患者预后的新型治疗策略铺平道路。
Br J Dermatol. 2025-3-27
J Dent Res. 2025-1
Brief Funct Genomics. 2024-7-19
Technol Cancer Res Treat. 2024
J Stomatol Oral Maxillofac Surg. 2024-9
FEBS Open Bio. 2025-9
Pathol Res Pract. 2024-10
Cell Commun Signal. 2024-4-2